Scribe Therapeutics Inc. (NASDAQ:SCTX – Get Free Report) major shareholder Bio Fund Ii L.P. Ah purchased 333,333 shares of the business’s stock in a transaction on Monday, July 27th. The stock was purchased at an average cost of $15.00 per share, for a total transaction of $4,999,995.00. Following the completion of the acquisition, the insider directly owned 2,385,075 shares of the company’s stock, valued at approximately $35,776,125. The trade was a 16.25% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.
Scribe Therapeutics Price Performance
Shares of SCTX stock opened at $19.48 on Friday. Scribe Therapeutics Inc. has a 12-month low of $17.31 and a 12-month high of $25.49.
Wall Street Analysts Forecast Growth
Separately, Wall Street Zen raised Scribe Therapeutics to a “hold” rating in a research report on Saturday.
Featured Articles
- Five stocks we like better than Scribe Therapeutics
- Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector
- Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case
- Apple’s Record Quarter Could Not Outrun Its Guidance Problem
- McKesson’s Compounding Keeps Adding Up
Receive News & Ratings for Scribe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scribe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
-sa-logo-1200x675.png){kind=logo}